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Characterization of metabolites in inﬁltrating
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Gliomas are routinely graded according to histopathological criteria established by the World Health Organization.
Although this classiﬁcation can be used to understand some of the variance in the clinical outcome of patients, there
is still substantial heterogeneity within and between lesions of the same grade. This study evaluated image-guided
tissue samples acquired from a large cohort of patients presenting with either new or recurrent gliomas of grades II–IV
using ex vivo proton high-resolutionmagic angle spinning spectroscopy. The quantiﬁcation ofmetabolite levels revealed
several discrete proﬁles associated with primary glioma subtypes, as well as secondary subtypes that had undergone
transformation to a higher grade at the time of recurrence. Statistical modeling further demonstrated that these
metabolomic proﬁles could be differentially classiﬁed with respect to pathological grading and inter-grade conversions.
Importantly, the myo-inositol to total choline index allowed for a separation of recurrent low-grade gliomas on different
pathological trajectories, the heightened ratio of phosphocholine to glycerophosphocholine uniformly characterized
several forms of glioblastomamultiforme, and the onco-metabolite D-2-hydroxyglutarate was shown to help distinguish
secondary fromprimary grade IV glioma, aswell as grade II and III fromgrade IV glioma. These data provide evidence that
metabolite levels are of interest in the assessment of both intra-grade and intra-lesional malignancy. Such information
could be used to enhance the diagnostic speciﬁcity of in vivo spectroscopy and to aid in the selection of the most appro-
priate therapy for individual patients. © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd.
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INTRODUCTION
Gliomas are tumors of the central nervous system that are
routinely graded on a scale of I to IV according to histopa-
thological criteria developed by the World Health Organization
(WHO) (1,2). Whereas grade I gliomas are considered to be
benign and can typically be treated through surgical interven-
tion, inﬁltrating gliomas of grades II–IV present a number of chal-
lenges in making an accurate diagnosis and in selecting the most
appropriate therapy. Some of the complications associated with
the management of inﬁltrating gliomas stem from the fact that
individual lesions are spatially heterogeneous and small tissue
samples obtained during biopsy or surgery may not represent
the most malignant region of the tumor. This situation is accen-
tuated following treatment, where a differential response to
therapy and tumor progression can cause additional ambiguity.
Because clinical outcomes for glioma can be quite variable, it is
important to provide criteria to more accurately assess the char-
acteristics that change both within and between pathological
grades. A further complication is that grade II and III gliomas
often undergo malignant transformation at the time of recur-
rence, which may necessitate more aggressive therapy (3–6).
This raises the question of whether individual gliomas develop
de novo (primary glioma) at a given grade or arise as a result of
transformation from a less malignant lesion (secondary glioma)
that was not detected previously. As lesions of the same histo-
logical grade may arise by different mechanisms, the designation
of primary and secondary glioma may have important clinical
consequences for the optimization of treatment (7).
Recent ﬁndings have indicated that the metabolite characteris-
tics of the lesion are valuable for the investigation of underlying
differences in malignancy. In vivo metabolite imaging provides a
unique opportunity for the evaluation of spatial and temporal
changes in the lesion and surrounding tissue that can be used to
direct tissue sampling at the time of resection, as well as for the se-
lection and monitoring of therapy. The lesion-wide data obtained
using this approach are synergistic with recent results from
genome-wide sequencing and informatics-driven analyses that
identify different subtypes of glioma with genetic characteristics.
The ability to infer themutational status of isocitrate dehydrogenase
(IDH) genes through non-invasive MRSI of D-2-hydroxyglutarate
(2HG) is an example with strong prognostic implications. This is a
signiﬁcant breakthrough in the realm of cancer diagnostics (8,9),
because it indicates that the evaluation of new therapies that
target the IDH pathway could be achieved non-invasively (10–13).
The primary goal of this study was to use the NMR technique of
proton high-resolution magic angle spinning (1H HR-MAS) spec-
troscopy to characterize the ex vivo metabolite proﬁles of patho-
logically distinct glioma subtypes at the time of initial diagnosis
and at subsequent transformation. By collecting a large cohort of
image-guided tissue samples, we sought to evaluate the hypoth-
esis that different glioma subtypes have characteristic metabo-
lite proﬁles that can aid in the prediction of the malignant
potential. The information obtained may be used directly for
improved categorization of ex vivo tissue samples, or can be
translated into an in vivo setting to provide non-invasive metab-
olite imaging methods to direct tissue sampling, to monitor
therapy and to make informed decisions about the effective-
ness of different treatment strategies.
MATERIALS AND METHODS
Patient population
Our institutionally approved study comprised 126 patients
receiving surgical resection as a result of suspected new or
recurrent WHO grade II, III or IV glioma, who provided informed
consent for image-guided tissue samples to be taken from areas
designated for resection on the basis of clinical criteria. The
diagnosis of grade was subsequently conﬁrmed by a single
pathologist on the basis of standard histological criteria (Table 1).
Pre-operative MRI and MRS
Pre-operative MR examinations were conducted using either
1.5- or 3-T whole-body MR scanners (GE Healthcare Technologies,
Milwaukee, Wisconsin, USA) with an eight-channel, phased-array head
coil for signal reception (MRIDevices, Knaresborough,UnitedKingdom).
The data obtained included three-dimensional T1-weighted and
T2-weighted anatomic images, six-directional diffusion-
weighted imaging acquired in the axial plane (TR/TE = 1000/108
ms; voxel size, 1.7 × 1.7 × 3 mm3; b = 1000 s/mm2) and, in some
cases, lactate (Lac)-edited three-dimensional 1H MRSI. The lat-
ter applied point-resolved spectroscopic selection (PRESS) for
volume localization and very selective saturation (VSS) pulses
for lipid (Lip) signal suppression (excited volume, ~80 × 80 × 40
mm3; overpress factor, 1.5; TR/TE = 1104/144 ms; ﬁeld of view, 16
× 16 × 16 cm3; nominal voxel size, 1 × 1 × 1 cm3; ﬂyback echo-pla-
nar readout gradient in the superior-inferior direction; 712 dwell
points; sweep width, 988 Hz) (14). Assessment of breakdown of
the blood–brain barrier was made by administering a standard
dose of Gd-DTPA (gadopentetate dimeglumine; Magnevist) prior
to the acquisition of T1-weighted inversion recovery spoiled-
gradient echo (IRSPGR) images (TR/TE = 8.9/2.5 ms).
Post-processing of pre-operative MR examination
In vivo data from the pre-operative examination were transferred
to a Sun Ultra 10 workstation (Sun Microsystems, Santa Clara,
California, USA) and in-house software was applied to derive
Table 1. Patient population. Patients and tissue samples were stratiﬁed according to original World Health Orga-
nization (WHO) grade and recurrence status
Original WHO
grade
Total Newly diagnosed Recurrent
Number of patients
(tissue samples)
Number of patients
(tissue samples)
Number of patients
(tissue samples)
II 54 (114) 0 (0) 54 (114)
III 22 (39) 5 (7) 17 (32)
IV 50 (101) 35 (70) 15 (31)
Total 126 (254) 40 (77) 86 (177)
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estimates of diffusion and spectroscopic parameters. Maps of the
apparent diffusion coefﬁcient (ADC) were generated on a pixel-
by-pixel basis (15). The 1H MRSI data were processed in order to
quantify total choline (tCho) and N-acetylaspartate (NAA) levels,
from which maps of the choline to NAA index (CNI) could be de-
rived. The CNI values were generated from an iterative linear re-
gression-based algorithm that sequentially removes outlying
values (16), and represent changes in choline and NAA levels
relative to the normal voxels from the same subject.
Image-guided tissue sampling
The acquisition of pre-surgical in vivo MR data enabled the
locations for tissue sampling from individual lesions to be planned
prior to resection. Targets were selected from within the anatomi-
cal lesion (gadolinium-enhancing region and/or area of hyperin-
tensity on T2-weighted images) that demonstrated an ADC value
of less than 1.5 times the value in normal-appearing white matter
and/or had elevated CNI values (CNI > 3.0) from 1H MRSI. Figure 1
depicts the selection of targets for a patient with a grade IV glioma.
The CNI map highlights the relative elevation of choline species
and reduction in NAA, which are consistent with malignant tissue.
Two primary targets were deﬁned, with one showing a local CNI
maximum and the other corresponding to a region of hypoin-
tensity on the ADC map. Targets were designated from each
patient as spherical regions of interest with a diameter of 5 mm
on co-registered MR images using BrainLAB surgical navigation
software (BrainLAB Inc., Munich, Germany). Image-guided naviga-
tion was applied to locate tissue corresponding to predeﬁned tar-
gets, and the neurosurgeon provided samples from as close as pos-
sible to the target. The actual sample location was saved on the
BrainLAB workstation, and the corresponding coordinates were
transferred ofﬂine for subsequent reference. After excision, the tis-
sue samples were immediately bisected: half was snap frozen in
liquid nitrogen less than 1 min after removal and stored at –80 °C
for 1H HR-MAS spectroscopy; the other half was ﬁxed in 10% zinc
formalin, dehydrated by graded ethanols and embedded in
Paraplast Plus wax (McCormick Scientiﬁc, St. Louis, Missouri, USA)
using standardized techniques for pathological analysis.
Histological analysis of the tumor
A pathologist evaluated the slides prepared from tissue samples
with hematoxylin and eosin stains to determine the relative
contribution of tumor cells to the overall cellularity. A score of ‘0’
denoted neuropil without tumor, ‘1’ indicated an inﬁltrating tumor
margin containing detectable but not abundant numbers of tumor
cells, ‘2’ denoted a more cellular inﬁltrated zone, and ‘3’ denoted
highly cellular tumor with relatively few non-neoplastic cells. Tissue
samples containing tumor cells (scores > 0) were classiﬁed
according to WHO standards.
1H HR-MAS spectroscopy
Tissue samples weighing between 0.87 and 37.86mg (median, 9.77mg)
were evaluated. A 35-μL zirconia rotor (custom-designed by Varian,
Figure 1. Planning of image- and MRSI-guided tissue sampling. In vivo 1H MRS of a patient diagnosed with glioblastoma multiforme. Point-resolved
spectroscopic selection (PRESS) coverage deﬁned by yellow box; outer volume suppression (OVS) of lipid shown on periphery; map of the choline
to N-acetylaspartate (NAA) index (CNI) is overlaid on a T1-weighted inversion recovery spoiled-gradient echo (IRSPGR) post-Gd image. The corresponding
subsets of spectra covering the lesion are shownon the right with CNI values; voxel highlighted in green is designated as a putative tumor region on the basis
of elevated CNI within the contrast-enhancing lesion (A). The spectrum from the voxel highlighted in green is enhanced to show the relative metabolite
levels contributing to the CNI (B). A 5-mm-diameter target planned for surgical navigation based on this elevated CNI is shown on the T1-weighted post-
contrast image (C). An adjacent target based on restricted diffusion is shown on an apparent diffusion coefﬁcient (ADC) map as a regional hypointensity
(D). Cr, creatine; GPC, glycerophosphocholine; PC, phosphocholine; PCr, phosphocreatine; tCho, total choline ([Cho] + [PC] + [GPC]).
A. ELKHALED ET AL.
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Palo Alto, California, USA) was used with 3 μL of 99.9% atom-D deu-
terium oxide containing 0.75 wt% 3-(trimethylsilyl)propionic acid
(Sigma-Aldrich, St. Louis, Missouri, USA) for chemical shift
referencing. Data were acquired at 11.7 T at 1 °C with a spin rate
of 2250 Hz in a 4-mm gHX nanoprobe with a Varian INOVA 500-
MHz multi-nuclear spectrometer. The nanoprobe gHX is an
inverse probe, optimized for the direct detection of 1H and
the indirect detection of X-nuclei (13C, 31P, 15N), and equipped with
a magic angle gradient coil.
A rotor-synchronized, one-dimensional, Carr–Purcell–Meiboom–
Gill (CPMG) pulse sequence was run with TR/TE = 4 s/144 ms, 512
scans, 40 000 acquired points, 90° pulse and spectral width of 20
kHz for a total time of 35 min. A relatively long TE was used to
maximally suppress the macromolecular background for purposes
of metabolite ﬁtting. The electronic reference to access in vivo
concentrations (ERETIC) method was used to generate an artiﬁcial
electronic signal that served as an external standard for the estima-
tion of metabolite levels (17).
Pre-processing of the spectra was performed in the time domain
using the Java-based Magnetic Resonance User Interface (jMRUI)
(18). The estimation of relative one-dimensional metabolite levels
was achieved with the semi-parametric algorithm, high-resolution
quantum estimation (HR-QUEST), which ﬁts a customized basis set
of metabolites to the spectrum (19). The basis set used in this study
comprised spectra from 26 metabolite solutions commonly stud-
ied in the human brain (Sigma-Aldrich): NAA, free choline (Cho),
phosphocholine (PC), glycerophosphocholine (GPC), ethanolamine
(Eth), phosphoethanolamine (PE), creatine/phosphocreatine (Cr/
PCr), myo-inositol (MI), scyllo-inositol (SI), glucose (Glc), glycine
(Gly), total glutathione [tGSH: glutathione (GSH) + glutathione
disulﬁde (GSSG)], glutamate (Glu), glutamine (Gln), 2HG, γ-
aminobutyric acid (GABA), taurine (Tau), hypotaurine (hTau), threo-
nine (Thr), acetate (Ace), Lac, alanine (Ala), betaine (Bet), aspartate
(Asp), valine (Val) and succinate (Suc). It also included spectra for
potential contaminants owing to the surgical sterilization agents
methanol (MeOH) and ethanol (EtOH). Each spectrum was evalu-
ated by an experienced spectroscopist to visually assess the good-
ness of ﬁt, and to determine whether low spectral resolution or
signal-to-noise ratio had compromised the evaluation of the
metabolite levels. Tissue samples found to have ambiguous or
unreliable results were eliminated from subsequent analyses.
Statistical analyses
Tissue samples with tumor scores of 1–3 and metabolite levels
with Cramer–Rao error estimates of less than 11% were evalu-
ated. To assess the association of the metabolite parameters with
various pathological grades and inter-grade transitions, a pro-
portional odds logistic regression model, adjusted for repeated
measures, was applied to evaluate the probability of observing
grade outcomes corresponding to different levels of malignancy.
This model is written as:
logit p Yij ≤ K j Xi; Zi
   ¼ αK þ X ′ijβ þ Z ′ijbi; i ¼ 1;…;Nsubjects;
K ¼ 1;…; c–1
where Yij is the ordinal outcome for subject i with biopsy
measurement j (ranges from 1 to 4), c is the total number of
levels of the ordinal variable, Хij is the design matrix for the ﬁxed
effects, Ζij is the design matrix for the random effects, αK are rows
corresponding to the jth biopsy specimen, and β and bi are the
vectors of ﬁxed and random parameters. The intercepts are ﬁxed
and category dependent. The odds ratio and p value for each
variable are reported. The ordinal-valued outcome mixed effect
models were analyzed using PROC GENMOD in SAS (SAS
Institute Inc., Cary, North Carolina, USA) v.9.2.
Statistical tests with p values of less than 0.05 were considered
to be signiﬁcant. Metabolites predictive of pathological grade
when adjusted for repeated specimen sampling were deemed
to be signiﬁcant predictors and are presented in the results.
Because of the exploratory nature of the study, no adjustment
for type I error was included.
The second aspect of the analysis concerned the classiﬁcation
of glioma subtypes among relevant groups. Logistic ridge
regression models with automatic feature selection were used
to determine whether metabolite parameters derived from
HR-MAS spectra could jointly predict pathological grades and
inter-grade transitions. Classiﬁcation accuracy was deﬁned as:
(number of true positives + number of true negatives)/(sample to-
tal). These accuracies were adjusted for multiple tissue samples per
patient by repeatedly training the models (100 training sets per
model) using only one randomly selected sample per patient,
and testing them using the remaining samples. Two feature selec-
tion methods were applied. An information gain ratio ﬁltering
method was ﬁrst employed to remove all variables that provided
no gain in classiﬁcation accuracy when evaluated individually,
followed by a wrapper-based feature selection method for the
evaluation of the worth of subsets of features and selection of the
best parsimonious model that was encountered. Average receiver
operating characteristic (ROC) curves were generated to visualize
the classiﬁcation performance of each model for the sampled cut-
offs, and the average area under the curve (AUC) was calculated.
RESULTS
Summary of analyzed tumor tissue
The numbers of tissue samples that were determined by
pathological analysis to contain tumor are summarized
according to their grade at initial diagnosis in Table 1. A total
of 254 tumor samples acquired from 126 subjects were eval-
uated using 1H HR-MAS spectroscopy.
Distinguishing metabolite proﬁles on the basis of primary
glioma grade
To be included in the evaluation of proﬁles from primary grades,
samples from recurrent lesions were required to have the same
histological grade as that determined at initial diagnosis. As
shown in Table 2, 43 of the samples were grade II, 25 grade III
and 101 grade IV.
Results from the ex vivo 1H HR-MAS spectra were represented
in three different ways. Figure 2A–C shows spectra normalized
with respect to the area of the ERETIC peak and then averaged
to provide a single mean spectrum for each grade. These
composite spectra allowed a visual assessment of differences in
the relative patterns of the peaks. It should be noted that the
relatively high peaks corresponding to Lac were not considered
in the comparative analysis as evidence indicates that they
cannot reliably reﬂect in vivo levels (20). Figure 2D shows
deviations in mean metabolite levels for samples from primary
grade III and IV gliomas relative to the levels in primary grade
II, with signiﬁcant increases or decreases in metabolites being
highlighted in red and green, respectively. Table 2 provides the
CHARACTERIZATION OF METABOLITES IN INFILTRATING GLIOMAS
NMR Biomed. 2014; 27: 578–593 © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/nbm
581
Ta
b
le
2.
M
et
ab
ol
ite
le
ve
ls
of
pr
im
ar
y
gl
io
m
a.
Re
la
tiv
e
m
et
ab
ol
ite
le
ve
ls
fo
r
ea
ch
su
bt
yp
e
of
gl
io
m
a,
di
sp
la
ye
d
as
m
ea
n
±
st
an
da
rd
er
ro
r
of
th
e
m
ea
n
(S
EM
);
no
un
its
ar
e
ex
pr
es
se
d
ow
in
g
to
th
e
T 2
de
pe
nd
en
ce
of
th
e
C
ar
r–
Pu
rc
el
l–
M
ei
bo
om
–G
ill
(C
PM
G
)
ac
qu
is
iti
on
G
ra
de
II
(n
=
43
)
G
ra
de
III
(n
=
25
)
G
ra
de
IV
(n
=
10
1)
O
ve
ra
ll
G
ra
de
II
ve
rs
us
III
G
ra
de
III
ve
rs
us
IV
G
ra
de
II
ve
rs
us
IV
M
ea
n
le
ve
ls
±
SE
M
O
dd
s
ra
tio
s
(9
5%
C
I)
N
um
be
r
of
ﬁ
tt
ed
sp
ec
tr
al
sa
m
pl
es
p
va
lu
es
N
A
A
29
±
6
24
±
6
12
±
2
0.
94
6
(0
.9
06
–0
.9
89
)
0.
92
7
(0
.8
75
–0
.9
81
)
0.
92
9
(0
.8
73
–0
.9
88
)
17
8
22
0.
01
N
S
0.
00
9
0.
02
C
ho
38
±
7
64
±
9
30
±
4
0.
97
9
(0
.9
59
–0
.9
99
)
33
21
47
N
S
N
S
0.
04
N
S
PC
51
±
7
83
±
15
67
±
8
33
20
29
N
S
0.
06
N
S
N
S
tC
ho
14
4
±
19
18
3
±
18
11
2
±
8
0.
99
6
(0
.9
92
–0
.9
99
)
0.
98
6
(0
.9
84
–0
.9
96
)
39
23
53
0.
02
N
S
0.
00
07
0.
08
PE
11
0
±
14
20
3
±
31
13
2
±
12
1.
01
0
(1
.0
03
–1
.0
18
)
29
17
47
N
S
0.
00
8
N
S
N
S
(P
)C
r
18
7
±
23
16
6
±
20
95
±
7
0.
99
1
(0
.9
86
–0
.9
95
)
0.
98
9
(0
.9
83
–0
.9
95
)
0.
98
8
(0
.9
81
–0
.9
94
)
37
23
50
<
0.
00
01
N
S
0.
00
01
0.
00
02
M
I
38
2
±
44
32
1
±
40
17
6
±
20
0.
99
5
(0
.9
92
–0
.9
99
)
39
23
45
0.
04
N
S
N
S
0.
07
G
ly
15
2
±
23
26
9
±
34
18
5
±
20
0.
99
7
(0
.9
94
–0
.9
99
)
25
20
45
N
S
0.
08
0.
02
N
S
tG
SH
35
±
4
57
±
20
61
±
6
1.
03
2
(1
.0
07
–1
.0
58
)
14
7
47
N
S
0.
09
N
S
0.
01
G
lu
19
9
±
21
27
8
±
43
29
6
±
28
32
22
57
N
S
0.
12
N
S
0.
09
G
ln
12
7
±
21
20
9
±
35
14
9
±
9
27
19
50
N
S
0.
14
0.
06
N
S
2H
G
32
±
4
34
±
4
0*
0.
90
7
(0
.8
69
–0
.9
47
)
0.
83
2
(0
.7
53
–0
.9
20
)
0.
82
7
(0
.7
32
–0
.9
35
)
17
13
10
1
<
0.
00
01
N
S
0.
00
03
0.
00
2
Th
r
39
±
9
82
±
18
74
±
12
1.
01
9
(1
.0
08
–1
.0
03
)
16
13
42
N
S
0.
07
N
S
0.
02
PC
/G
PC
11
1
±
37
18
0
±
81
22
9
±
31
31
13
23
N
S
N
S
N
S
N
S
M
C
I
32
5
±
27
19
2
±
22
16
9
±
14
0.
99
3
(0
.9
89
–0
.9
66
)
0.
99
2
(0
.9
86
–0
.9
99
)
0.
99
2
(0
.9
87
–0
.9
96
)
38
22
42
0.
00
02
0.
02
N
S
0.
00
05
tC
ho
/(
P)
C
r
98
±
13
12
4
±
14
14
0
±
16
1.
00
7
(1
.0
00
–1
.0
13
)
37
21
76
0.
04
N
S
N
S
0.
08
2H
G
, D
-2
-h
yd
ro
xy
gl
ut
ar
at
e;
C
ho
,f
re
e
ch
ol
in
e;
C
r,
cr
ea
tin
e;
G
ln
,g
lu
ta
m
in
e;
G
lu
,g
lu
ta
m
at
e;
G
ly
,g
ly
ci
ne
;G
PC
,g
ly
ce
ro
ph
os
ph
oc
ho
lin
e;
G
SH
,g
lu
ta
th
io
ne
;G
SS
G
,g
lu
ta
th
io
ne
di
su
lﬁ
de
;
M
C
I,
m
yo
-in
os
ito
lt
o
to
ta
lc
ho
lin
e
in
de
x;
M
I,
m
yo
-in
os
ito
l;
N
A
A
,N
-a
ce
ty
la
sp
ar
ta
te
;N
S,
no
t
si
gn
iﬁ
ca
nt
;P
C
,p
ho
sp
ho
ch
ol
in
e;
PC
r,
ph
os
ph
oc
re
at
in
e;
PE
,p
ho
sp
ho
et
ha
no
la
m
in
e;
tC
ho
,
to
ta
lc
ho
lin
e
([C
ho
]
+
[P
C
]
+
[G
PC
]);
tG
SH
,t
ot
al
gl
ut
at
hi
on
e
([G
SH
]
+
[G
SS
G
]);
Th
r,
th
re
on
in
e.
*A
bs
en
ce
of
2H
G
re
so
na
nc
es
co
nﬁ
rm
ed
by
vi
su
al
in
sp
ec
tio
n.
A. ELKHALED ET AL.
wileyonlinelibrary.com/journal/nbm © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd. NMR Biomed. 2014; 27: 578–593
582
mean and standard error of individual metabolite levels esti-
mated using HR-QUEST and tested for signiﬁcant differences
between grades.
The mean spectrum for primary grade II gliomas (Fig. 2A) showed
prominent peaks corresponding to Cr/PCr, MI, GPC, PC, Cho and
NAA, with clear composite peaks corresponding to 2HG, Glu and
Gln. The tGSH resonances were relatively low. A key parameter that
distinguished primary grade II lesions from the other primary grades
(see Table 2) was the ratio ofMI to tCho (MCI), whichwas higher than
for both grade III (p = 0.02) and grade IV (p = 0.0005) lesions. Thr,
which is a precursor to both Gly and acetyl-CoA, was either signiﬁ-
cantly lower or trending towards lower levels in primary grade II rel-
ative to primary grade III (p = 0.07) and grade IV (p = 0.02) lesions.
The mean spectrum from primary grade III glioma showed
prominent peaks from GPC, PC and Cho, that were higher rela-
tive to Cr/PCr and NAA than for the mean spectrum from grade
II glioma (Fig. 2B). There was also a more prominent Gly peak and
relatively low peaks from MI. Resonances corresponding to 2HG,
Glu and Gln were visible, as well as additional peaks from hTau.
The statistical analysis showed that, although there was a general
trend towards higher overall metabolite levels relative to primary
grade II lesions (Fig. 2D), only the reduction in MCI (p = 0.02)
and the increase in PE (p = 0.008) reached signiﬁcance (Table 2).
The mean spectrum from primary grade IV glioma (Fig. 2C)
showed relatively lower GPC, Cr/PCr and NAA peaks than both
of the lower grades, and lower MI and Gly peaks relative to
primary grade III glioma. There were no 2HG resonances seen
in individual primary grade IV samples, but relatively more PC
relative to GPC, and the presence of Lip peaks at 0.9 and 1.25
ppm that were either lower or absent in grades II and III. Tests
of signiﬁcance showed that the levels of NAA and Cr/PCr were
lower than in both grade II (p = 0.02 and 0.0002) and grade III
(p = 0.009 and 0.0001) gliomas. In addition, MCI was signiﬁcantly
lower (p = 0.0005) and the level of tGSH higher (p = 0.01) than in
primary grade II glioma, and the levels of Cho, tCho and Gly
were signiﬁcantly lower than in grade III glioma (p = 0.04,
0.0007 and 0.02).
The classiﬁcation models showed relatively high accuracy in
categorizing the metabolite data according to grade (Table 3).
There was an 84% accuracy in classifying primary grade II versus
Figure 2. Metabolite proﬁles of primary glioma. Mean Carr–Purcell–Meiboom–Gill (CPMG) spectra for glioma samples histologically deﬁned as grade II (n =
43) (A), grade III (n= 25) (B) and grade IV glioblastomamultiforme (GBM) (n= 114) (C). Deviation in quantiﬁedmeanmetabolite levels of grade II and IV glioma
relative to grade II glioma; reported levels are unitless owing to the T2 dependence of the CPMG acquisition (D). Signiﬁcant increases or decreases in the
metabolite levels displayed as residuals are highlighted in red and green, respectively. Signiﬁcance was deﬁned as p < 0.05 for the comparative analysis
among subtypes using the proportional odds logistic regression analysis. MeOH and EtOH are contaminants resulting from surgical sterilization procedures.
2HG, D-2-hydroxyglutarate; Ace, acetate; Ala, alanine; Asp, aspartate; Bet, betaine; Cho, free choline; Cr, PCr, creatine, phosphocreatine; Eth, ethanolamine;
EtOH, ethanol; GABA, γ-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Gly, glycine; GPC, glycerophosphocholine; GSH, glutathione; GSSG,
glutathione disulﬁde; hTau, hypotaurine; Ile, isoleucine; Lac, lactate; Leu, leucine; Lip, lipid; Lys, lysine; MCI, myo-inositol to total choline index; MeOH, meth-
anol; MI, myo-inositol; NAA, N-acetylaspartate; PC, phosphocholine; PE, phosphoethanolamine; SI, scyllo-inositol; Suc, succinate; Tau, taurine; tCho, total cho-
line ([Cho] + [PC] + [GPC]); tGSH, total glutathione ([GSH] + [GSSG]); Thr, threonine; Val, valine.
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IV glioma, which underscored the utility of features such as 2HG,
tGSH and MCI. Classiﬁcation of primary grade II versus III glioma
showed an accuracy of 73%, with the signiﬁcant differences
being in MCI, PE and Gly. Finally, grade III gliomas were separated
from glioblastoma multiforme (GBM) with an accuracy of 92%
based on higher levels of 2HG, tCho, NAA and Cr/PCr. ROC curves
that demonstrate the sensitivity and speciﬁcity for these classiﬁca-
tions are shown in Fig. 3A.
Table 3. Glioma classiﬁcation models. Performance of the machine learning classiﬁcation schemes, as well as average receiver
operating characteristic (ROC) curve areas
Number of (patients, tissue samples)
per grade or transformation
Classiﬁcation
model
Average classiﬁcation
accuracy ± SD (%)
Average ROC
curve area
Primary glioma II (21,43) II versus III 73.1 ± 4.2 0.761
III (15,25) III versus IV 92.4 ± 2.8 0.960
IV (50, 101) II versus IV 84.4 ± 3.2 0.869
Recurrent low-grade
glioma
GII → II versus GII → III 69.3 ± 4.4 0.746
GII → II (21, 43) GII → III versus GII → IV 72.5 ± 3.1 0.550
GII → III (26, 52) GII → II versus GII → IV 73.6 ± 5.7 0.745
GII → IV (8, 19) GII → II versus TFD 69.9 ± 5.1 0.726
Primary versus
secondary grade III
GII → III (26, 52) III versus GII → III 76.7 ± 5.6 0.676
III (15, 25)
Primary versus
secondary GBM
IV (50, 101) IV versus GII → IV 94.4 ± 0.8 0.854
GII → IV (8, 19) IV versus GIII → IV 95.6 ± 0.9 0.756
GIII → IV (7, 14) GII → IV versus GIII → IV 61.9 ± 4.1 0.698
GBM, glioblastoma multiforme; TFD, gliomas that have transformed to a higher grade of malignancy.
Average FPR (1 - specificity)Average FPR (1 - specificity)
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Figure 3. Average receiver operating characteristic (ROC) curves for the logistic ridge regression classiﬁcation models shown in Table 3: primary gli-
oma (A), recurrent low-grade glioma transformation status (B), primary versus secondary grade III (C), and primary versus secondary glioblastoma
multiforme (GBM) (D). The averaged curves represent the results of 100 training sets per classiﬁcation model. FPR, false positive rate; TFD, transformed
to a higher grade of malignancy; TPR, true positive rate.
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Transformation status for recurrent grade II glioma
As can be seen in Table 3, many of the lesions with an original
diagnosis of grade II glioma were found to have undergone trans-
formation to a higher pathological grade at recurrence. The largest
portion of the tissue samples (46%) showed transformation to
grade III (GII→III, n = 52) and 16% to grade IV (GII→IV, n = 19).
Peaks from themean spectra (see Fig. 4A–C) corresponding toMI,
Cr/PCr and NAA consistently discriminated gliomas that had
remained grade II (GII→II) from their transformed counterparts
(GII→III or V). As was the case for primary glioma samples, there
was a transition from GPC to PC as the dominant choline
resonance and an increase in the abundance of Lip for grade IV
lesions. Figure 4D demonstrates that transformation to higher
grade was associated with a progressive increase in metabolite
levels. Of particular interest is that the levels of PC (p = 0.05 and
0.005) and tGSH (p = 0.02 and 0.003) were signiﬁcantly higher for
both transitions, and that 2HG levels were signiﬁcantly higher
for GII→IV (p = 0.01). MCI showed an opposite trend, being lower
for both GII→III (p = 0.02) and GII→IV (p = 0.002) relative to GII→II.
The statistical analysis represented in Table 4 emphasizes the
signiﬁcance of these changes.
The statistical models created to discriminate GII→II versus
GII→III and GII→III versus GII→IV demonstrated classiﬁcation accura-
cies of 69% and 73%, respectively (Table 3; Fig. 3B). Lower levels of
tGSH in GII→II and elevated levels of PC/GPC in GII→IV were helpful
in distinguishing GII→III. Modeling the optimal classiﬁcation of GII→II
versus GII→IV provided an accuracy of 74%, and selected the
features of Asp, PC and tGSH as the strongest predictors of GII→IV,
whereas high MCI strongly favored GII→II. When comparing all
gliomas that had upgraded (GII→III,IV) with those that remained
low grade (GII→II), the classiﬁcation accuracy was 70%.
Primary versus secondary grade III glioma
There were 25 primary grade III (GIII) and 52 secondary grade III
(GII→III) gliomas. Table 5 indicates that the primary lesions had
signiﬁcantly higher Cho (p = 0.02), Gly (p = 0.03) and PC/GPC
(p = 0.03). The classiﬁcation model of GIII versus GII→III yielded an
Figure 4. Metabolite proﬁles of recurrent low-grade glioma. Mean Carr–Purcell–Meiboom–Gill (CPMG) spectra for glioma samples histologically
deﬁned according to malignant transformation status as grade II → II (n = 43) (A), grade II → III (n = 52) (B) and grade II → IV (n = 19) (C). Deviation
in quantiﬁed mean metabolite levels of grade II → III and II → IV glioma relative to grade II → II glioma; reported levels are unitless owing to the T2
dependence of the CPMG acquisition (D). Signiﬁcant increases or decreases in the metabolite levels displayed as residuals are highlighted in red
and green, respectively. Statistical signiﬁcance was deﬁned as p < 0.05 for the comparative analysis among subtypes using the proportional odds
logistic regression analysis. MeOH and EtOH are contaminants resulting from surgical sterilization procedures. 2HG, D-2-hydroxyglutarate; Ace, acetate;
Ala, alanine; Asp, aspartate; Bet, betaine; Cho, free choline; Cr, PCr, creatine, phosphocreatine; Eth, ethanolamine; EtOH, ethanol; GABA, γ-aminobutyric
acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Gly, glycine; GPC, glycerophosphocholine; GSH, glutathione; GSSG, glutathione disulﬁde; hTau,
hypotaurine; Ile, isoleucine; Lac, lactate; Leu, leucine; Lip, lipid; Lys, lysine; MCI, myo-inositol to total choline index; MeOH, methanol; MI, myo-inositol;
NAA, N-acetylaspartate; PC, phosphocholine; PE, phosphoethanolamine; SI, scyllo-inositol; Suc, succinate; Tau, taurine; tCho, total choline ([Cho] + [PC] +
[GPC]); tGSH, total glutathione ([GSH] + [GSSG]); Thr, threonine; Val, valine.
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Table 5. Metabolite levels of primary versus secondary grade III glioma. Relative metabolite levels for each subtype of glioma,
displayed as mean ± standard error of the mean (SEM); no units are expressed owing to the T2 dependence of the Carr–Pur-
cell–Meiboom–Gill (CPMG) acquisition
Primary grade III (n = 25) Grade II→ III (n = 52) Primary versus secondary grade III
Mean levels ± SEM Odds ratios (95% CI)
Number of ﬁtted spectral samples p values
Cho 64 ± 9 40 ± 4 1.021 (1.003–1.039)
21 48 0.02
NAA 24 ± 6 15 ± 3 1.019 (1.000–1.103)
8 19 0.05
Gly 269 ± 34 194 ± 20 1.004 (1.001–1.008)
20 39 0.03
PC/GPC 180 ± 81 79 ± 10 1.004 (1.000–1.008)
13 42 0.03
Cho, free choline; Gly, glycine; GPC, glycerophosphocholine; NAA, N-acetylaspartate; NS, not signiﬁcant; PC, phosphocholine.
Figure 5. Metabolite proﬁles of primary versus secondary glioblastoma multiforme (GBM). Mean Carr–Purcell–Meiboom–Gill (CPMG) spectra for glioma
samples histologically deﬁned as primary grade IV (n = 101) (A) and secondary grade III → IV (n = 14) (B) or grade II → IV (n = 19) (C). Deviation in
quantiﬁed mean metabolite levels of grade II → III and II → IV glioma relative to grade II → II glioma; reported levels are unitless owing to the T2
dependence of the CPMG acquisition (D). Signiﬁcant increases or decreases in the metabolite levels displayed as residuals are highlighted in red
and green, respectively. Statistical signiﬁcance was deﬁned as p < 0.05 for the comparative analysis among subtypes using the proportional odds
logistic regression analysis. MeOH and EtOH are contaminants resulting from surgical sterilization procedures. 2HG, D-2-hydroxyglutarate; Ace, acetate;
Ala, alanine; Asp, aspartate; Bet, betaine; Cho, free choline; Cr, PCr, creatine, phosphocreatine; Eth, ethanolamine; EtOH, ethanol; GABA, γ-aminobutyric
acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Gly, glycine; GPC, glycerophosphocholine; GSH, glutathione; GSSG, glutathione disulﬁde; hTau,
hypotaurine; Ile, isoleucine; Lac, lactate; Leu, leucine; Lip, lipid; Lys, lysine; MCI, myo-inositol to total choline index; MeOH, methanol; MI, myo-inositol;
NAA, N-acetylaspartate; PC, phosphocholine; PE, phosphoethanolamine; SI, scyllo-inositol; Suc, succinate; Tau, taurine; tCho, total choline ([Cho] + [PC] +
[GPC]); tGSH, total glutathione ([GSH] + [GSSG]); Thr, threonine; Val, valine.
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accuracy of 77%, and indicated that there were relative elevations
in GABA, Ala and GPC for primary lesions (Table 3; Fig. 3C).
Primary versus secondary GBM
There were 101 samples from primary grade IV and 33 from
secondary grade IV (GII→IV, n = 19; GIII→IV, n = 14) glioma. The
most obvious differences in the mean spectra (Fig. 5A–C) were
the variations in the levels and relative contributions of GPC
and PC, the lack of 2HG and the increase in the abundance of
Lip. Overall, metabolite levels appeared to be higher in the
lesions that arose from grade II glioma (Fig. 5C, D). Statistical anal-
ysis indicated that tCho, 2HG and Asp were signiﬁcantly higher in
GII→IV samples relative to the de novo GIV (Fig. 5D and Table 6).
Cr/PCr (p = 0.05) and MCI (p = 0.04) were signiﬁcantly different
for GII→IV samples. Figure 6 shows spectra from a primary grade
IV glioma (red) and a secondary grade IV glioma (blue) that arose
from a recurrent grade II lesion. Differences in the portions of
spectra corresponding to resonances of 2HG are clearly visible.
The classiﬁcation models for the discrimination between
primary versus secondary grade IV glioma were highly accurate
(Table 3; Fig. 3D), with themost valuable parameter being the level
of 2HG. Accuracies for GIV versus GII→IV and GIV versusGIII→IV models
were 94% and 96%, respectively. Other parameters, such as tCho
and Asp, were found to be useful for distinguishing the GIV versus
GII→IV subgroups. The comparison between secondary GBM
subtypes (GII→IV versus GIII→IV) showed an accuracy of only 62%.
DISCUSSION
This study has provided a characterization of the spectral proﬁles
for inﬁltrating gliomas. A critical ﬁnding was that 1H HR-MAS
spectroscopic techniques enabled an accurate classiﬁcation of
these diverse subtypes with respect to standard histological
criteria and changes that are associated with malignant transfor-
mation at recurrence. This could be important for oncologists in
selecting the most appropriate treatment for individual patients
in cases in which there is no tissue available from the initial
diagnosis. A further critical ﬁnding was that several of the
ex vivo metabolite changes observed could be translated into
the in vivo setting. These results are of interest for improving
the characterization of glioma for non-invasive diagnosis, plan-
ning of tissue sampling and surgical resection (21–27).
Table 7 summarizes the important clinical implications of our
study according to relevant metabolite ﬁndings. A key applica-
tion of these data is the guidance of tissue sampling at the time
of initial diagnosis, given the importance of locating the most
malignant region of the tumor for pathological grading. This
study suggests that tCho, NAA, Cr/PCr, MI and Lac levels offer
the most compelling information for determination of the tumor
grade from an in vivo perspective. These metabolites are also of
particular interest for studying lesion heterogeneity, especially in
the case of grade IV glioma, where representative tissue samples
may be difﬁcult to obtain at the time of surgical resection. Similar
criteria are also proposed in Table 7 for directing tissue sampling
with regard to the determination of whether recurrent low-grade
gliomas have undergone transformation to a higher grade, and
may therefore require more aggressive treatment.
The progressive reduction in MCI for lesions that have
transformed from grade II to grade III or IV is a potentially impor-
tant marker that can be monitored in vivo using short-echo 1H
MRSI, and may be able to predict transformation to a higher
grade or distinguish between recurrent tumor and reactive
gliosis (28). Whether other in vivo metabolite data can be used
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to make a non-invasive diagnosis of malignant transforma-
tion will depend on the signal-to-noise ratio of the various
peaks, the accuracy of the quantitative methods used and
the magnitude of the changes that need to be detected.
Although in vivo detection of tGSH and 2HG has also been
reported (9,29–33), these peaks have low signal-to-noise
ratios and are located in regions with overlapping spectra
from other metabolites. The relative contributions of GPC
and PC (4,27,34,35) are a strong ex vivo marker for the detec-
tion of transformation to grade IV that may relate to speciﬁc
oncogenic pathways (36), however their contributions to the
tCho peak cannot be separated with in vivo 1H MRSI. One
possibility which may therefore be of interest for future stud-
ies of malignant transformation is the use of ultrahigh-ﬁeld
MR scanners to obtain in vivo 31P MRSI spectra for assessing
changes in PC/GPC.
The third application of this study (Table 7) is to distinguish
between primary and secondary lesions, which is especially
pertinent for selecting therapy and understanding the diversity
of outcomes between patients who were originally thought to
have similar pathology. We showed that secondary grade IV gli-
omas that arise from grade II (Fig. 3C, D) display a very unique
proﬁle that is visually characterized by elevations in 2HG, PC,
PC/GPC ratio and hTau. The latter metabolite is an intermediate
in the biosynthesis of Tau and a sulfur-bearing antioxidant like
GSH, capable of reducing reactive oxygen species under condi-
tions of oxidative stress (37,38). A previous HR-MAS study has
also indicated that hTau is an important ex vivo biomarker for
the separation of grade IV glioma and metastatic lesions (39).
The relationship between the levels of 2HG and mutations in
the IDH genes (IDH1 and IDH2) for up to 70% of lesions
diagnosed as grade II glioma has important implications for
distinguishing between primary and secondary gliomas (10).
Although previous reports in the literature have indicated that
5–12% of primary grade IV gliomas carry IDH mutations
(10,11,40), none of the tumors that presented as primary grade
IV glioma in this study showed detectable levels of 2HG. This
discrepancy may be a result of variations in patient populations
between institutions and/or the time at which lesions were
originally diagnosed. In either case, 2HG remains an important
metabolite to monitor in vivo.
The evaluation of the genomic properties of primary and
secondary grade III gliomas may also help in our understanding
of how treatment history inﬂuences the processes associated
with malignant progression. Although a substantial number of
primary grade III glioma samples were found to be IDH
mutant on the basis of immunohistochemistry, and to have
detectable levels of 2HG, there were other differences in their
metabolite proﬁle relative to secondary anaplastic glioma,
which included signiﬁcantly lower levels of the tumor markers
Gly (41) and PC/GPC. By contrast, transition from primary grade
III to secondary grade IV glioma was mainly associated with an
increase in tCho. This provides additional motivation for
collecting tissue samples in the area of the lesion that is seen
to have high tCho from 1H MRSI. Although it was not assessed
in this ex vivo study, results from in vivo measurements of Lac
suggest that this metabolite can also identify important targets
for directed tissue sampling (42,43).
Despite attempts to optimize the experimental design of
this study, there were some inherent limitations that should
be noted. The ﬁrst concerns the possibility of the presence of
differences in tumor cellularity between the portions of the
samples that were used for histological and metabolite
analysis. For this reason, we did not normalize metabolite
levels by measures of tumor cellularity, but rather sought to
identify robust patterns that were consistent across tumors
of similar grade. The second is that the acquisition parameters
used for this HR-MAS study meant that the estimated
metabolite levels were weighted by their T2 relaxation times.
Despite this T2 editing, the current literature has not indicated
any statistically signiﬁcant difference in T2 values between
gliomas of different grade (34,44). Moreover, a CMPG
sequence was employed with varying TEs to determine
whether differences in metabolite T2 values could be observed
between grade II (n = 3) and grade IV (n = 4) samples, which
represent opposite ends of the tumor cellularity spectrum,
and no substantial difference was observed for the choline
species, Cr/PCr and MI (data not shown).
A third limitation is that the number of samples analyzed in our
study did not allow for further stratiﬁcation on the basis of histo-
logical subtypes of low-grade glioma, such as astrocytoma,
oligodendroglioma and the mixed oligoastrocytoma (1,2).
Previous studies have indicated that there are differences in
metabolite parameters among these subtypes (45,46). This may
have inﬂuenced the accuracy with which we were able to
distinguish between lesions that transformed from grade II to
grade III versus those that remained grade II at recurrence. The fact
that there was a higher proportion of lesions with an oligoden-
droglioma subtype in the population that remained grade II
(57.1%) and a smaller proportion of lesions with this subtype in
the group that transformed to grade III (36.0%) may explain
sources of variance that were not adequately captured in the
classiﬁcation models of this study. Ongoing studies in our
institution are collecting a larger number of samples in order to
allow for a stratiﬁcation of lesions by their respective histological
subtype, and hence to observe how cellular origin relates to
proﬁles of metabolism.
CONCLUSIONS
The results obtained in this study have elucidated the associa-
tion between 1H MRSI and the standard histological grading
of gliomas that is used clinically for the diagnosis of patients
and the determination of appropriate treatments. Metabolite
proﬁles were able to help differentiate between primary glioma
subtypes, predict the transformation of recurrent grade II to
either grade III or IV, and deﬁne the pathological trajectories
of primary and secondary glioma of grades III and IV. These
novel ﬁndings suggest that the discrete metabolomic proﬁles
observed may be related to genomic or epigenomic abnormal-
ities of speciﬁc glioma subtypes. Metabolites of signiﬁcance
from ex vivo analyses that can readily be observed using clinical
MR scanners may also offer in vivo biomarkers to clinicians who
are attempting to diagnose patients non-invasively and to
monitor treatment. The metabolite proﬁles that have been
identiﬁed could also help to characterize intra-lesional
malignancy in a manner that is not currently addressed by
the histopathological grading scheme, and may therefore aid
in the delineation of targets for radiation planning and surgical
intervention. This is critical for the clinical management of
patients with glioma, and provides motivation for future
studies that will examine the relationship between 1H MRSI and
genetic, epigenetic and biological variations in these lesions.
CHARACTERIZATION OF METABOLITES IN INFILTRATING GLIOMAS
NMR Biomed. 2014; 27: 578–593 © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/nbm
591
Acknowledgements
We would like to acknowledge support from the Brain Tumor
Research Center at the University of California, San Francisco
(UCSF) in collecting tissue samples, as well as from the Magnetic
Resonance Laboratory at UCSF for the use of the spectrometer.
Grant funding was provided by the National Institutes of Health
(NIH) Brain Tumor SPORE P50 CA097257, NIH PO1 CA118816, NIH
RO1 CA127612 and NIH Clinical Center Intramural Program.
REFERENCES
1. Lois DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A,
Scheithauer BW, Kleihues P. The 2007 WHO classiﬁcation of tumours
of the central nervous system. Acta Neuropathol. 2007; 114(2): 97–109.
2. Lopes MBS, VandenBerg SR, Scheithauer BW. The World Health Orga-
nization classiﬁcation of nervous system tumors in experimental
neuro-oncology. In Levine AJ, Schmidek HH (eds). Molecular Genetics
of Nervous System Tumors. Wiley-Liss: New York; 1993, pp. 1–36.
3. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer
BW, Jenkins RB, Bucknew JC. Transformation of low grade glioma
and correlation with outcome: an NCCTG database analysis.
J. Neurooncol. 2011; 104(1): 253–259.
4. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malig-
nant transformation. Nat. Rev. Cancer 2011; 11(12): 835–848.
5. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A,
Ellison DW, Baker SJ. Cooperativity within and among Pten, p53, Rb
pathways induces high-grade astrocytoma in adult brain. Cancer Cell
2011; 19(3): 305–316.
6. Philips HS, Kharbanda S, Chen R, Forrest WF, Sorian RH, Wu TD, Misra
A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z,
Feuerstein BF, Aldape K. Molecular subclasses of high-grade glioma
predict prognosis, delineate a pattern of disease progression, and re-
semble stages in neurogenesis. Cancer Cell 2006; 9(3): 157–173.
7. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD,
Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly
M, Tamayo P, Weir B, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler
HS, Hodgson JG, James CD, Sarkaria JN, Brennen C, Kahn A, Spellman
PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM,
Hayes DN. The Cancer Genome Atlas Research Network. Integrated
genomic analysis identiﬁes clinically relevant subtypes of glioblas-
toma characterized by abnormalities in PDGFRA, IDH1, EGFR, and
NF1. Cancer Cell 2010; 17: 98–110.
8. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R,
Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Mag-
netic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade
gliomas. Sci. Transl. Med. 2012; 4: 116ra5.
9. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR,
Vander Heiden MG, Sorenson GS. Detection of 2-hydroxyglutarate
in IDH-mutated glioma patients by in vivo spectral-editing and 2D
correlation magnetic resonance spectroscopy. Sci. Transl. Med.
2012; 4: 116ra4.
10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I,
Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A,
Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B,
Bigner DD. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.
2009; 360: 765–773.
11. ParsonsDW, Jones S, ZhangX, Lin JC, Leary RJ, Angenendt P, Mankoo P,
Carter H, Siu I, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S,
Nikolskaya T, Nikolsky Y, Busam D, Tekleab H, Diaz LA Jr, Hartigan J,
Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ,
Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B,
Velculescu VE, Kinzler KW. An integrated genomic analysis of human
glioblastoma multiforme. Science 2008; 321: 1807–1812.
12. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris
S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M,
Delattre JY. IDH1 or IDH2 mutations predict longer survival and
response to temozolomide in low-grade gliomas. Neurology 2010;
75: 1560–1566.
13. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M,
Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G,
Weller M, Loefﬂer M, von Deimling A. Patients with IDH1 wild type
anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated
glioblastomas, and IDH1 mutation status accounts for the unfavorable
prognostic effect of higher age: implications for classiﬁcation of
gliomas. Acta Neuropathol. 2010; 120: 707–718.
14. Park I, Chen AP, Zierhut M, Ozturk-Isik E, Vigneron DB, Nelson SJ.
Implementation of 3T lactate-edited 3D 1H MR spectroscopic
imaging with ﬂyback echo-planar readout for glioma patients. Ann.
Biomed. Eng. 2011; 39: 193–204.
15. Basser PJ, Pierpaoli C. Microstructural and physiological features of
tissues elucidated by quantitative diffusion-tensor MRI. J. Magn.
Reson. B, 1996; 111: 209–219.
16. McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ. An automated
technique for the quantitative assessment of 3D-MRSI data from pa-
tients with glioma. J. Magn. Reson. Imaging 2001; 13: 167–177.
17. Albers MJ, Butler TN, Rahwa I, Bao N, Keshari KR, Swanson MG,
Kurhanewicz, J. Evaluation of the ERETIC method as an improved
quantitative reference for 1H HR-MAS spectroscopy of prostate tis-
sue. Magn. Reson. Med. 2009; 61: 525–532.
18. Stefan D, Cesare FD, Andrasescu A, Popa E, Lazariev A, Vescovo E,
Strbak O, Williams S, Starcuk Z, Cabanas M, van Ormondt D,
Graveron-Demily D. Quantitation of magnetic resonance spectros-
copy signals: the jMRUI software package. Meas. Sci. Technol. 2009;
20: 104035(9pp).
19. Ratiney H, Albers MJ, Rabeson H, Kurhanewicz J. Semi-parametric
time-domain quantiﬁcation of HR-MAS data from prostate tissue.
NMR Biomed. 2010; 23: 1–13.
20. Opstad KS, Bell BA, Grifﬁths JR, Howe FA. An assessment of the effects
of sample ischaemia and spinning time on the metabolic proﬁle of
brain tumour biopsy specimens as determined by high-resolution
magic angle spinning 1H NMR. NMR Biomed. 2008; 21(10): 1138–1147.
21. Opstad KS, Wright AJ, Bell A, Grifﬁths JR, Howe FA. Correlations
between in vivo 1H MRS and ex vivo 1H HR-MAS metabolite measure-
ments in adult human gliomas. J. Magn. Reson. Imaging 2010; 31:
289–297.
22. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM,
Bajcsy R, Nelson SJ. Identifying malignant transformations in recur-
rent low grade gliomas using high resolution magic angle spinning
spectroscopy. Artif. Intell. Med. 2012; 55(1): 61–70.
23. Vettukattil R, Gulati M, Sjobakk TE, Jakola AS, Kvernmo NA, Torp SH,
Bathen TF, Gulati S, Gribbestad IS. Differentiating diffuse World
Health Organization grade II and IV astrocytomas with ex vivo mag-
netic resonance spectroscopy. Neurosurgery 2013; 72(2): 186–195.
24. Sjobakk TE, Vettukattil R, Gulati M, Gulati S, Lundgren S, Gribbestad
IS, Torp SH, Bathen TF. Metabolic proﬁles of brain metastases. Int. J.
Mol. Sci. 2013; 14(1): 2104–2118.
25. Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, Revert A, Ferrer P,
Llacer JL, Piotto M, Assemat O, Celda B. 1H and 13C HR-MAS spectros-
copy of intact biopsy samples ex vivo and in vivo 1H MRS study of
human high grade gliomas. NMR Biomed. 2004; 17(4): 191–205.
26. Rutter A, Hugenholtz H, Saunders JK, Smith IC. Classiﬁcation of brain
tumors by ex vivo 1H NMR spectroscopy. J. Neurochem. 1995; 64(4):
1655–1661.
27. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G,
Barrios L, Schenetti L, Cerdan S, Garcia-Martin ML. 1H HR-MAS and
genomic analysis of human tumor biopsies discriminate between
high and low grade astrocytomas. NMR Biomed. 2009; 22: 629–637.
28. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A,
Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic
measure differentiates tumor from treatment effects in GBM.
Neuro-Oncol. 2010; 12: 1152–1161.
29. Opstad KS, Provencher SW, Bell BA, Grifﬁths JR, Howe FA. Detection of
elevated glutathione in meningiomas by quantitative in vivo 1H MRS.
Magn. Reson. Med. 2003; 49: 632–637.
30. Thelwal PE, Yemin AY, Gillian TL, Simpson NE, Kasibhatla MS, Rabbani
ZN, MacDonald JM, Blackband SJ, Gamcsik MP. Noninvasive in vivo
detection of glutathione metabolism in tumors. Cancer Res. 2005; 65:
10149–10153.
31. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson
SJ. MR spectroscopic imaging of glutathione in the white and gray
matter at 7 T with an application to multiple sclerosis. Magn. Reson.
Imaging 2010; 28(2): 163–170.
32. Choi C, Ganji SK, DeBerardinis RJ, Rakheja D, Kovacs Z, Yang XL,
Mashimo T, Taisanen JM, Marin-Valencia I, Pascual JM, Madden CJ,
Mickey BE, Malloy CR, Bachoo RM, Maher EA. 2-Hydroxyglutarate
detection by magnetic resonance spectroscopy in IDH-mutated
patients with gliomas. Nat. Med. 2012; 18(4): 624–629.
A. ELKHALED ET AL.
wileyonlinelibrary.com/journal/nbm © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd. NMR Biomed. 2014; 27: 578–593
592
33. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger
MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E,
Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI,
Wu H, Fantin VR, Liau LM. Non-invasive detection of 2-
hydroxyglutarate and other metabolites in IDH1 mutant glioma
patients using magnetic resonance spectroscopy. J. Neurooncol.
2012; 107(1): 197–205.
34. Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing
compounds in human astrocytomas studied by 1H NMR spectroscopy
in vivo and in vitro. J. Neurochem. 1994; 63(4): 1538–1543.
35. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12:
413–439.
36. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD,
Ronen SM. Reduced phosphocholine and hyperpolarized lactate
provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibi-
tion in glioblastoma. Neuro-Oncol. 2012; 14(3): 315–325.
37. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of
taurine, hypotaurine and their metabolic precursor. Biochem. J.
1988; 256(1): 251–255.
38. Brand A, Leibfritz D, Hamprecht B, Dringen R. Metabolism of cysteine in
astroglial cells: synthesis of hypotaurine and taurine. J. Neurochem.
1998; 71: 827–832.
39. Wright AJ, Fellows GA, Grifﬁths JR, Wilson M, Bell BA, Howe FA. Ex
vivo HRMAS of adult brain tumours: metabolite quantiﬁcation and
assignment of tumour biomarkers. Molec. Cancer, 2010; 9: 66.
40. Presner JR, Chinaiyan AM. Metabolism unhinged: IDH mutations in
cancer. Nat. Med. 2011; 17: 291–293.
41. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolu-
tionmagic angle spinningmagnetic resonance spectroscopy detects gly-
cine as a biomarker in brain tumors. Int. J. Oncol. 2010; 36(2): 301–306.
42. Chang SM, Nelson SJ, Vandenberg S, Cha S, Prados M, Butowski N,
McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. Integration of
preoperative anatomic and metabolic physiologic imaging of newly
diagnosed glioma. J. Neurooncol. 2009; 92(3): 401–415.
43. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S,
Nelson SJ. Evaluation of MR markers that predict survival in patients
with newly diagnosed GBM prior to adjuvant therapy. J. Neurooncol.
2009; 91(1): 69–81.
44. Li Y, Srinivasan R, Ratiney H, Lu Y, Chang SM, Nelson SJ. Comparison
of T1 and T2 metabolite relaxation times in glioma and normal brain
at 3T. J. Magn. Reson. Imaging 2008; 28(2): 342–350.
45. Chawla S, Oleaga L, Wang S, Krejza J, Woo JH, O’Rourke DM, Judy KD,
Grady MS, Melhem ER, Poptani H. Role of proton magnetic
resonance spectroscopy in differentiating oligodendrogliomas and
astrocytomas. J. Neuroimaging 2010; 20(1): 3–8.
46. Huang J, Gholami B, Agar NYR, Norton I, Haddad WM, Tannenbaum
AR. Classiﬁcation of astrocytomas and oligodendrogliomas from
mass spectrometry data using sparse kernel machines. Engineering
in Medicine and Biology Society, EMBC, Annual International Confer-
ence of the IEEE, Boston, Massachusetts, USA, 2011; 7965–7968.
CHARACTERIZATION OF METABOLITES IN INFILTRATING GLIOMAS
NMR Biomed. 2014; 27: 578–593 © 2014 The Authors. NMR in Biomedicine published by John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/nbm
593
